<DOC>
	<DOCNO>NCT02217904</DOCNO>
	<brief_summary>This study evaluate safety , tolerability , pharmacokinetics , anti-retroviral therapy ( ART ) activity MK-8591 monotherapy ART-naive , human immunodeficiency virus-1 ( HIV-1 ) infect participant . The primary hypothesis safe tolerable dose MK-8591 , true mean difference plasma HIV-1 ribonucleic acid ( RNA ) reduction baseline MK-8591 placebo least 0.5 log ( base10 ) copies/mL .</brief_summary>
	<brief_title>A Study MK-8591 Anti-Retroviral Therapy-Naive , Human Immunodeficiency Virus-1 Infected Participants ( MK-8591-003 )</brief_title>
	<detailed_description />
	<criteria>Nonpregnant , nonbreast feeding , postmenopausal surgically sterile female Female reproductive potential agrees use ( male partner use ) two acceptable method birth control Male agree use acceptable method contraception study 90 day last dose trial drug Has stable baseline health , HIV infection Has significantly abnormal electrocardiogram Is HIV1 positive Have screen plasma HIV1 RNA ≥ 10,000 copies/mL within 30 day prior treatment phase study . For inclusion Panel MK8591 Extended Observation , participant must also screen plasma HIV1 RNA ≤ 25,000 copies/mL within 30 day prior treatment phase . Is ART naive Has receive investigational agent market ART within 30 day trial drug administration Is diagnose HIV1 infection &gt; = 3 month prior screen Is willing receive ART treatment phase study Has evidence mutation confer resistance nucleoside reverse transcriptase inhibitor ( NRTIs ) Is mentally legally institutionalized/incapacitated , significant emotional problem , history clinically significant psychiatric disorder last 5 year Has history clinically significant endocrine , gastrointestinal , cardiovascular , hematological , hepatic , immunological ( outside HIV1 infection ) , renal , respiratory , genitourinary , major neurological abnormality diseases Has history cancer ( malignancy ) Has history significant multiple and/or severe allergy , anaphylactic reaction drug food Is positive hepatitis B surface antigen Has history chronic Hepatitis C Had major surgery lose 500 mL blood 4 week prior screen visit Has participate another investigational trial within 4 week prior dose visit Will use medication , prescribe drug , herbal remedy 4 week prior dose trial drug , posttrial visit Consumes excessive amount alcohol , caffeinated beverage , tobacco product Uses illicit drug history drug abuse within prior 2 year</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>